This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
by Zacks Equity Research
BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.
Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros
by Zacks Equity Research
Novo Nordisk (NVO) enters into negotiations to acquire a majority stake in BIOCORP, followed by a tender offer to acquire all remaining shares in BIOCORP for a total equity value of 154 million Euros.
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
by Zacks Equity Research
Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy of Opdivo plus Yervoy.
Bayer (BAYRY) & Cedilla to Co-Develop Novel Cancer Therapies
by Zacks Equity Research
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
by Zacks Equity Research
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
AstraZeneca (AZN) Discontinues Brazikumab Development
by Zacks Equity Research
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
by Zacks Equity Research
PepGen (PEPG) shares fall after FDA places clinical hold on a study evaluating potential treatment for myotonic dystrophy.
J&J (JNJ) Submits NDA for Single Tablet Combo to Treat PAH
by Zacks Equity Research
J&J (JNJ) submits a new drug application for a single tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension.
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
by Zacks Equity Research
Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
by Zacks Equity Research
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
by Zacks Equity Research
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
by Zacks Equity Research
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.
How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Akero Therapeutics, Inc. (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
by Zacks Equity Research
A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.
Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Akero Therapeutics, Inc. (AKRO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.
Why Earnings Season Could Be Great for Akero Therapeutics (AKRO)
by Zacks Equity Research
Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.
Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 42.6% upside potential for Akero Therapeutics, Inc. (AKRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
by Zacks Equity Research
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.